Hematopoietic regulation through Ott1-dependent alternative splicing

通过 Ott1 依赖的选择性剪接进行造血调节

基本信息

  • 批准号:
    8579535
  • 负责人:
  • 金额:
    $ 39.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-08-01 至 2018-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hematopoiesis depends on the dual ability of the hematopoietic stem cell (HSC) to balance self-renewal and proliferation while replenishing progenitors to supply the body's needs over a lifetime. Stress brought on by conditions such as infection, anemia or toxic chemotherapy can disrupt this critical balance resulting in bone marrow failure and ultimately death. Understanding the pathways controlling self-renewal and proliferation will provide pharmacologic opportunities to protect vital HSC function. Ott1, a gene isolated as a fusion partner in t(1;22) acute megakaryocytic leukemia, is essential for maintaining self-renewal of HSCs during proliferative stress. Ott1 is a spliceosome component, has a transcriptional activation/repression domain, RNA Recognition Motifs and possesses binding sites for Histone Deacetylase (Hdac), Notch-effector Rbpj and the histone methyltransferase Set1db. Although Ott1 has been found to interact with viral RNAs, no physiologic targets have been identified. Preliminary data shows Ott1 interacts with a region of the c-Mpl gene involved in alternative splicing. C-Mpl is the receptor for Thrombopoietin (Thpo), which is critical for megakaryocyte development and maintaining both quiescence and proliferative function in HSCs during stress. Low level c- Mpl responses support HSC quiescence and high signaling responses allow proliferation, yet the modulating mechanism is not known. Analysis of HSCs from conditionally-deleted Ott1 mice show a dramatic increase in the ratio of Mpl-TR isoform to Mpl-FL (full length). Mpl-TR has described dominant negative function in vitro and impairs HSC engraftment in vivo. Ott1 binds in complex to the alternatively spliced region on c-Mpl RNA. In addition, Ott1-dependent epigenetic modifications to the alternatively spliced region of c-Mpl, including histone deacetylation and H3K4me3 marking provide a potential mechanism capable of regulating the Mpl-TR:Mpl-FL ratio and thereby modulating response to Thpo. Activation of Notch also favors Mpl-TR production which through Ott1 interaction with Rbpj, may explain how the bone marrow niche regulates HSC quiescence and proliferation during stress. The molecular mechanism Ott1-mediated underlying c-Mpl alternative splicing will be investigated and the role of associated epigenetic modifiers established. The link between Ott1, Rbpj, and c-Mpl will be examined as a mechanism for Notch to control HSC Thpo response. Finally, the effects of Mpl-TR on HSC proliferation and quiescence in relation to withstanding hematopoietic stress will be determined. The comprehensive strategy utilizing genetic complementation, chemical inhibitors, and antisense oligonucleotides to target the pathways regulating c-Mpl alternative splicing in this proposal may identify novel pharmacologic approaches to address human disease arising from impaired HSC function such as recovery from cytotoxic chemotherapy, graft failure after stem cell transplantation and bone marrow failure syndromes such as aplastic anemia.
描述(申请人提供):造血依赖于造血干细胞(HSC)平衡自我更新和增殖的双重能力,同时补充祖细胞以满足身体终生需要。感染、贫血或毒性化疗等疾病带来的压力会破坏这种关键的平衡,导致骨髓衰竭,最终导致死亡。了解控制自我更新和增殖的途径将为保护重要的HSC功能提供药理学机会。Ott1基因是在t(1;22)急性巨核细胞白血病中分离的一个融合伴侣基因,在增殖应激过程中对维持HSCs的自我更新是必不可少的。Ott1是一个剪接体成分,具有转录激活/抑制结构域和RNA识别基序,并与组蛋白脱乙酰酶(HDAC)、Notch效应分子Rbpj和组蛋白甲基转移酶Set1db结合。虽然已经发现Ott1与病毒RNA相互作用,但还没有确定生理靶点。初步数据显示,Ott1与参与选择性剪接的c-MPL基因区域相互作用。C-MPL是血小板生成素(Thpo)的受体,它对巨核细胞的发育以及在应激状态下维持HSCs的静止和增殖功能至关重要。低水平的c-MPL反应支持HSC的静止,而高水平的信号反应允许HSC增殖,但其调控机制尚不清楚。对条件缺失OTT1小鼠的HSCs的分析表明,MPL-TR亚型与MPL-FL(全长)的比率显著增加。MPL-tr在体外具有显性的负性功能,并在体内损害HSC的植入。Ott1与c-MPL RNA上的选择性剪接区以复合体结合。此外,对c-MPL选择性剪接区的OTT1依赖的表观遗传修饰,包括组蛋白去乙酰化和H3K4me3标记,提供了一种潜在的机制,能够调节MPL-TR:MPL-FL比率,从而调节对Thpo的反应。Notch的激活也有利于MPL-tr的产生,这可能是通过Ott1与Rbpj的相互作用来解释骨髓生态位如何在应激状态下调节HSC的静止和增殖。OTT1介导的c-MPL选择性剪接的分子机制将被研究,并建立相关的表观遗传修饰物的作用。将研究Ott1、Rbpj和c-mpl之间的联系,作为Notch控制HSC Thpo反应的机制。最后,将确定MPL-tr对HSC增殖和静止的影响,这与耐受造血应激有关。在这项建议中,利用遗传互补、化学抑制剂和反义寡核苷酸来靶向调节c-mpl选择性剪接的途径的综合策略可能会找到新的药理学方法来解决因HSC功能受损而引起的疾病,如细胞毒性化疗后的恢复、干细胞移植后的移植物衰竭以及再生障碍性贫血等骨髓衰竭综合征。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Glen D Raffel其他文献

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)
  • DOI:
    10.1182/blood-2023-190037
  • 发表时间:
    2023-11-02
  • 期刊:
  • 影响因子:
  • 作者:
    John DiPersio;Brenda W Cooper;Hyung C Suh;Divya Koura;Lea Bernard;Nirali N. Shah;Roland B. Walter;Miguel-Angel Perales;Markus Mapara;Roni Tamari;Michael R. Loken;Kyle Breitschwerdt;Sritama Nath;Glen D Raffel;Guenther Koehne
  • 通讯作者:
    Guenther Koehne
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
  • DOI:
    10.1182/blood-2024-205641
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    John F. DiPersio;Guenther Koehne;Nirali N. Shah;Lea Bernard;Hyung C Suh;Divya Koura;Miguel Angel Perales;Roni Tamari;Muhammad Umair Mushtaq;Joseph E. Maakaron;Michael R. Loken;Darren A Stanizzi;Melissa M. Lee-Sundlov;Sanjana Thosar;Sharon L Hyzy;Glen D Raffel;Brenda W Cooper
  • 通讯作者:
    Brenda W Cooper

Glen D Raffel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Glen D Raffel', 18)}}的其他基金

Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
  • 批准号:
    10163910
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
  • 批准号:
    10409804
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
  • 批准号:
    10601077
  • 财政年份:
    2020
  • 资助金额:
    $ 39.63万
  • 项目类别:
Hematopoietic regulation through Ott1-dependent alternative splicing
通过 Ott1 依赖的选择性剪接进行造血调节
  • 批准号:
    8708200
  • 财政年份:
    2013
  • 资助金额:
    $ 39.63万
  • 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
  • 批准号:
    7336370
  • 财政年份:
    2005
  • 资助金额:
    $ 39.63万
  • 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
  • 批准号:
    7176783
  • 财政年份:
    2005
  • 资助金额:
    $ 39.63万
  • 项目类别:
Mouse model of infant acute megakaryocytic leukemia.
婴儿急性巨核细胞白血病小鼠模型。
  • 批准号:
    7008162
  • 财政年份:
    2005
  • 资助金额:
    $ 39.63万
  • 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
  • 批准号:
    6851221
  • 财政年份:
    2005
  • 资助金额:
    $ 39.63万
  • 项目类别:
Mouse model of infant acute megakaryocytic leukemia
婴儿急性巨核细胞白血病小鼠模型
  • 批准号:
    7563228
  • 财政年份:
    2005
  • 资助金额:
    $ 39.63万
  • 项目类别:
Nongenotoxic conditioning for HIV cure transplantation approaches
HIV治愈移植方法的非基因毒性调理
  • 批准号:
    9891829
  • 财政年份:
  • 资助金额:
    $ 39.63万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了